Adline Chem Lab Ltd Stock Price Today (NSE: ADLINE)
Fundamental Score
Adline Chem Lab Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Adline Chem Lab Ltd share price today is ₹13.70, up +0.00% on NSE/BSE as of 23 June 2026. Adline Chem Lab Ltd (ADLINE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.91 (Cr). The 52-week high for ADLINE share price is ₹19.08 and the 52-week low is ₹7.60.
Adline Chem Lab Ltd Share Price Chart — NSE/BSE Historical Performance
Adline Chem Lab Ltd share price chart: 21.45% return over the past month. 52-week high ₹19.08, 52-week low ₹7.60.
Adline Chem Lab Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹13.70 | ₹13.70 | ₹13.70 | ₹13.70 | 0.00 (Cr) | |
| ₹13.70 | ₹13.70 | ₹13.70 | ₹13.70 | 0.00 (Cr) | |
| ₹13.70 | ₹13.70 | ₹13.70 | ₹13.70 | 0.00 (Cr) | |
| ₹13.70 | ₹13.70 | ₹13.70 | ₹13.70 | 0.00 (Cr) | |
| ₹13.70 | ₹13.70 | ₹13.70 | ₹13.70 | 0.00 (Cr) | |
| ₹13.70 | ₹13.70 | ₹13.70 | ₹13.70 | 0.00 (Cr) | |
| ₹13.70 | ₹13.70 | ₹13.70 | ₹13.70 | 100.00 (Cr) | |
| ₹13.05 | ₹13.05 | ₹13.05 | ₹13.05 | 0.00 (Cr) | |
| ₹13.05 | ₹13.05 | ₹13.05 | ₹13.05 | 0.00 (Cr) | |
| ₹13.05 | ₹13.05 | ₹13.05 | ₹13.05 | 0.00 (Cr) |
Adline Chem Lab Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹13.70 | ₹13.70 | ₹13.70 | ₹13.70 | +0.00% | |
| ₹11.28 | ₹13.70 | ₹11.28 | ₹13.70 | +21.45% | |
| ₹12.50 | ₹12.50 | ₹10.75 | ₹11.28 | -9.76% | |
| ₹13.32 | ₹13.32 | ₹12.05 | ₹12.50 | -6.16% | |
| ₹13.56 | ₹15.48 | ₹12.34 | ₹14.02 | +3.39% | |
| ₹8.78 | ₹12.31 | ₹8.78 | ₹12.31 | +40.21% | |
| ₹8.40 | ₹9.21 | ₹7.60 | ₹8.78 | +4.52% | |
| ₹14.15 | ₹14.89 | ₹8.40 | ₹8.40 | -40.64% | |
| ₹17.95 | ₹17.95 | ₹14.65 | ₹14.89 | -17.05% | |
| ₹17.95 | ₹17.95 | ₹17.95 | ₹17.95 | +0.00% | |
| ₹14.90 | ₹18.10 | ₹14.82 | ₹17.95 | +20.47% | |
| ₹18.25 | ₹18.25 | ₹14.25 | ₹15.65 | -14.25% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap pharma play with a history of losses, decreasing promoter stake, and no institutional interest – stay away.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Adline Chem Lab closed its trading window for designated persons from April 1, 2026, ahead of Q4 FY26 results. The window will reopen 48 hours after the official announcement of the audited standalone financial results for the quarter and fiscal year ending March 31, 2026.
CORE STORY (THE REAL GAME)
Adline Chem Lab is a micro-cap pharma company attempting a turnaround by focusing on marketing activities after discontinuing production in 2019. The key narrative revolves around whether it can leverage its existing product portfolio and outsourced manufacturing to achieve sustainable profitability.
- Trading window closed ahead of Q4 results
- Micro-cap stocks are often driven by speculative trading
- Turnaround hopes based on cost optimization and renewed marketing efforts
- Positive surprise in upcoming Q4 results
- New order wins or contracts
- Significant change in promoter holding
- Micro/SME cap — liquidity risk is high
- History of losses and discontinued production
- Promoters have decreased stake in the last 12 months
No FII or DII holding. Promoter holding at 29.61% with a decrease in the last 12 months.
Indian biopharma sector is receiving government support through initiatives like Biopharma SHAKTI, but Adline Chem Lab's micro-cap status makes it unlikely to benefit significantly.
Negative free cash flow of ₹-0.35 Cr over the last 5 years
The company's future hinges on its ability to execute its marketing strategy and achieve profitability through outsourced manufacturing. However, the odds are stacked against it.
Primary Thesis Risk
Inability to achieve sustainable profitability and potential liquidity crunch.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Adline Chem Lab Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Adline Chem Lab Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ADLINE across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Robust Profit Growth (22.22%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Weak Interest Coverage (0.08x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-0.35 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (29.61%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Adline Chem Lab Ltd vs Pharmaceuticals & Biotechnology Peers
Peer Comparison - Pharmaceuticals & Biotechnology
Compare Adline Chem Lab Ltd with 1 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Adline Chem Lab LtdAdline Chem Lab...Selected✓ ADLINE • 524604 | 14.1/100 | ₹13.70₹14 | ₹4.91₹4.91 | — — | — — | — — | — — | 14.49%Good 14.49% Good | — — | 0.00% |
Ind SwiftInd Swift... INDSWFTLTD • 524652 | 45.8/100 | ₹15.76₹16 | ₹92.30₹92.30 | 11.80Average 11.8 Average | — — | 11.86%Average 11.86% Average | — — | 18.19%Excellent 18.19% Excellent | 9.35%Good 9.35% Good | 0.00% |
Adline Chem Lab Ltd Quarterly Performance
Latest quarterly metrics for ADLINE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
22.22%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
14.49%
Compounded annual net profit growth over 5 years
Adline Chem Lab Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ADLINE — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Adline Chem Lab Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Adline Chem Lab Ltd (ADLINE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Adline Chem Lab Ltd
About ADLINE (Adline Chem Lab Ltd)
Adline Chem Lab Ltd is a pioneering force in the pharmaceutical and biotechnology sectors, dedicated to advancing global health through innovative research, development, and manufa...cturing. With a steadfast commitment to scientific excellence, ADLINE strives to address unmet medical needs and improve patient outcomes worldwide. The company's core values of integrity, quality, and innovation underpin every aspect of its operations, from cutting-edge research laboratories to state-of-the-art manufacturing facilities. ADLINE is driven by a team of highly skilled scientists, engineers, and healthcare professionals who are passionate about pushing the boundaries of medical science and delivering life-changing therapies to those who need them most. ADLINE's diverse portfolio of pharmaceutical and biotechnology products encompasses a wide range of therapeutic areas, reflecting its dedication to comprehensive healthcare solutions. The company specializes in developing and commercializing novel treatments for infectious diseases, gastrointestinal disorders, and musculoskeletal conditions, addressing critical healthcare challenges faced by patients across the globe. Furthermore, ADLINE provides essential medicines for pediatric care, women's health, and respiratory ailments, ensuring that patients of all ages have access to high-quality healthcare solutions. These products are available in various formulations, including tablets, capsules, liquids, and injectables, to cater to diverse patient needs and preferences. Beyond its commitment to human health, ADLINE also extends its expertise to veterinary medicine, providing animal healthcare solutions that promote the well-being of pets and livestock. The company develops and manufactures a range of veterinary pharmaceuticals and nutritional supplements, addressing the specific health needs of animals and supporting the agricultural industry. Additionally, ADLINE is dedicated to advancing medical knowledge through educational initiatives, providing healthcare professionals with the latest scientific insights and clinical guidelines. This holistic approach to healthcare, encompassing both human and animal well-being, positions ADLINE as a trusted partner in promoting global health and improving the quality of life for all.
Company Details
Key Leadership
Latest News
ADLINE Share Price: Frequently Asked Questions
What is the current share price of Adline Chem Lab Ltd?
Adline Chem Lab Ltd (ADLINE) trades at ₹13.70 on NSE and BSE. Market cap ₹4.91 (Cr). Educational data only.
What is the P/E ratio of Adline Chem Lab Ltd?
Adline Chem Lab Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Adline Chem Lab Ltd?
Adline Chem Lab Ltd has a Bull Run score of 14.1/100 based on 25+ financial parameters.
Does Adline Chem Lab Ltd pay dividends?
Adline Chem Lab Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Adline Chem Lab Ltd?
Adline Chem Lab Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Adline Chem Lab Ltd?
Adline Chem Lab Ltd has debt-to-equity of N/A.
Is Adline Chem Lab Ltd a good investment?
Bull Run gives Adline Chem Lab Ltd a score of 14.1/100. This is not investment advice — consult a SEBI-registered advisor.